



PEER-REVIEW REPORT

Name of journal: *World Journal of Transplantation*

Manuscript NO: 83833

Title: Sodium-Glucose Cotransporter-2 Inhibitor Use in Kidney Transplant Recipients

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 00506112

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Professor

Reviewer's Country/Territory: Greece

Author's Country/Territory: United States

Manuscript submission date: 2023-02-10

Reviewer chosen by: AI Technique

Reviewer accepted review: 2023-02-11 08:48

Reviewer performed review: 2023-02-12 09:41

Review time: 1 Day

Scientific quality	<input checked="" type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Novelty of this manuscript	<input checked="" type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty
Creativity or innovation of this manuscript	<input checked="" type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation



Scientific significance of the conclusion in this manuscript	<input checked="" type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input type="checkbox"/> Anonymous <input checked="" type="checkbox"/> Onymous
	Conflicts-of-Interest: <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

1. The authors describe their concerns on urinary tract infections (UTI) with the use of SGLT2i; actually, more genital infections (GI) have been reported in people with diabetes on treatment with SGLT2i , most commonly in women. I would suggest to separate UTI from GI in this mini review. 2. Concerns regarding amputations in people with diabetes have been reported only with canagliflozin; I suggest to keep the concerns for risk of amputations only for canagliflozin.



PEER-REVIEW REPORT

Name of journal: *World Journal of Transplantation*

Manuscript NO: 83833

Title: Sodium-Glucose Cotransporter-2 Inhibitor Use in Kidney Transplant Recipients

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer’s code: 04152279

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer’s Country/Territory: China

Author’s Country/Territory: United States

Manuscript submission date: 2023-02-10

Reviewer chosen by: AI Technique

Reviewer accepted review: 2023-02-15 11:52

Reviewer performed review: 2023-02-21 07:00

Review time: 5 Days and 19 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Novelty of this manuscript	<input checked="" type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty
Creativity or innovation of this manuscript	<input checked="" type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation



Scientific significance of the conclusion in this manuscript	<input checked="" type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

SGLT2i are a novel oral hypoglycemic agent that has received a lot of attention in the fields of nephrology and cardiology for its great benefits. The article derived a conclusion that the research and utilization of SGLT2i is critical not only for long-term patients, graft and cardiovascular outcomes using these drugs, but also for the enhancing of management of diabetes, chronic kidney disease and cardiovascular diseases in kidney transplant recipients. This review is novel in concept and has certain clinical application value. But there are still some problems in the followings: 1.In the section of result, eGFR, proteinuria, blood pressure and other data are listed tediously, you could improve the key results, and conduct targeted discussion according to the described results. 2.The content of the limitation could be simplified. The discussion of irrelevant content can be reduced, and the limitation of the research content can be highlighted.